These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32168760)

  • 21. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with
    Tolmachev V; Yim CB; Rajander J; Perols A; Karlström AE; Haaparanta-Solin M; Grönroos TJ; Solin O; Orlova A
    Contrast Media Mol Imaging; 2017; 2017():8565802. PubMed ID: 29097939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.
    Altai M; Honarvar H; Wållberg H; Strand J; Varasteh Z; Rosestedt M; Orlova A; Dunås F; Sandström M; Löfblom J; Tolmachev V; Ståhl S
    Eur J Med Chem; 2014 Nov; 87():519-28. PubMed ID: 25282673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.
    Wållberg H; Grafström J; Cheng Q; Lu L; Martinsson Ahlzén HS; Samén E; Thorell JO; Johansson K; Dunås F; Olofsson MH; Stone-Elander S; Arnér ES; Ståhl S
    J Nucl Med; 2012 Sep; 53(9):1446-53. PubMed ID: 22872744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
    Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
    Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Evaluation of [
    Oroujeni M; Garousi J; Andersson KG; Löfblom J; Mitran B; Orlova A; Tolmachev V
    Cells; 2018 Sep; 7(9):. PubMed ID: 30231504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.
    Tolmachev V; Friedman M; Sandström M; Eriksson TL; Rosik D; Hodik M; Ståhl S; Frejd FY; Orlova A
    J Nucl Med; 2009 Feb; 50(2):274-83. PubMed ID: 19164241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
    Wållberg H; Löfdahl PK; Tschapalda K; Uhlén M; Tolmachev V; Nygren PK; Ståhl S
    Protein Expr Purif; 2011 Mar; 76(1):127-35. PubMed ID: 21029777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update: affibody molecules for molecular imaging and therapy for cancer.
    Orlova A; Feldwisch J; Abrahmsén L; Tolmachev V
    Cancer Biother Radiopharm; 2007 Oct; 22(5):573-84. PubMed ID: 17979560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of composition of cysteine-containing peptide-based chelators on biodistribution of
    Oroujeni M; Andersson KG; Steinhardt X; Altai M; Orlova A; Mitran B; Vorobyeva A; Garousi J; Tolmachev V; Löfblom J
    Amino Acids; 2018 Aug; 50(8):981-994. PubMed ID: 29728916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
    Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A
    Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.
    Altai M; Perols A; Tsourma M; Mitran B; Honarvar H; Robillard M; Rossin R; ten Hoeve W; Lubberink M; Orlova A; Karlström AE; Tolmachev V
    J Nucl Med; 2016 Mar; 57(3):431-6. PubMed ID: 26659353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
    Sandberg D; Tolmachev V; Velikyan I; Olofsson H; Wennborg A; Feldwisch J; Carlsson J; Lindman H; Sörensen J
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1337-1346. PubMed ID: 28261749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
    Orlova A; Magnusson M; Eriksson TL; Nilsson M; Larsson B; Höidén-Guthenberg I; Widström C; Carlsson J; Tolmachev V; Ståhl S; Nilsson FY
    Cancer Res; 2006 Apr; 66(8):4339-48. PubMed ID: 16618759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
    Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z
    Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
    Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
    Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
    Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
    Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
    Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
    J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.
    Leitao CD; Rinne SS; Altai M; Vorontsova O; Dunås F; Jonasson P; Tolmachev V; Löfblom J; Ståhl S; Orlova A
    Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32545760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of an optimized scaffold for affibody molecules.
    Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
    J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.